Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 45.8 | 56.2 | 58.1 | 54.3 | 56.3 | 61.2 | 66.0 | 67.7 |
| Operating profit | $bn | 20.1 | 23.5 | ||||||
| Net profit | $bn | 4.6 | 11.5 | 11.8 | 4.9 | 4.3 | 4.2 | 10.4 | 24.8 |
| EPS reported | $ | 2.37 | 5.83 | ||||||
| Operating cashflow per share | $ | 10.73 | 11.34 | ||||||
| Capex per share | $ | 0.68 | 0.69 | ||||||
| FCF per share | $ | 10.04 | 10.65 | ||||||
| Free cash flow | $bn | 17.8 | 18.9 | ||||||
| Net debt | $bn | 63.1 | 70.1 | ||||||
| Book value equity | $bn | -3.27 | -4.58 | ||||||
| Book value per share | $ | -1.84 | -2.59 | ||||||
| Number of shares | m | 1,774 | 1,772 | ||||||
| DPS (TTM paid) | $ | 6.56 | 6.92 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 96.41 | 50.60 | ||||||
| P/B LTM | x | -123.96 | -113.77 | ||||||
| P/S LTM | x | 6.63 | 7.90 | ||||||
| P/FCF LTM | x | 22.75 | 27.63 | ||||||
| EV/EBITDA LTM | x | 26.61 | 24.49 | ||||||
| EV/Sales LTM | x | 7.67 | 8.96 | ||||||
| Earnings Yield LTM | % | 1.04% | 1.98% | ||||||
| FCF Yield | % | 4.40% | 3.62% | ||||||
| Quality | |||||||||
| ROE | % | -129.24% | -202.50% | ||||||
| ROIC | % | 12.97% | 16.73% | ||||||
| Operating margin | % | 32.85% | 35.53% | ||||||
| Gross margin | % | 70.24% | 76.25% | ||||||
| FCF/Sales | % | 29.13% | 28.59% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -0.84% | +338.35% | ||||||
| Sales Growth YoY | % | +8.57% | +10.68% | ||||||
| Net Income Growth YoY | % | -1.22% | +333.42% | ||||||
| FCF Growth | % | -0.09% | -4.13% | ||||||
| Operating Profit Growth | % | +119.89% | +159.46% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.88% | 2.35% | ||||||
| Dividend Growth | % | +5.81% | +5.49% | ||||||
| Payout Ratio | % | 277.26% | 275.84% | ||||||
| FCF/Debt | x | 0.26 | 0.23 | ||||||
| Net Debt/EBITDA | x | 3.62 | 2.90 | ||||||
| EBIT/Net interest | x | 6.94 | 8.15 | ||||||
| Net debt/market cap | % | 15.57% | 13.45% | ||||||
| Net debt/Equity | x | -19.30 | -15.30 | ||||||
| Gross debt/equity | x | -21.12 | -17.65 | ||||||
ETFs that hold AbbVie
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard Morningstar Value ETF | VTV | 6 | 1.75% |
| Vanguard Dividend Appreciation ETF | VIG | 10 | 2.05% |
| iShares Russell 1000 Value ETF | IWD | 9 | 1.26% |
| Vanguard High Dividend Yield ETF | VYM | 5 | 1.96% |
| State Street Health Care Select Sector SPDR ETF | XLV | 3 | 7.60% |
| JPMorgan Equity Premium Income ETF | JEPI | 10 | 1.77% |
| iShares Core Dividend Growth ETF | DGRO | 3 | 3.06% |
| Vanguard Russell 1000 Value ETF | VONV | 9 | 1.17% |
| Vanguard Health Care ETF | VHT | 3 | 6.45% |
| WisdomTree U.S. Quality Dividend Growth Fund | DGRW | 9 | 2.36% |
Funds with AbbVie among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard Morningstar Value ETF | VTV | 6 | 1.75% |
| Vanguard Dividend Appreciation ETF | VIG | 10 | 2.05% |
| iShares Russell 1000 Value ETF | IWD | 9 | 1.26% |
| Vanguard High Dividend Yield ETF | VYM | 5 | 1.96% |
| State Street Health Care Select Sector SPDR ETF | XLV | 3 | 7.60% |
| JPMorgan Equity Premium Income ETF | JEPI | 10 | 1.77% |
| iShares Core Dividend Growth ETF | DGRO | 3 | 3.06% |
| Vanguard Russell 1000 Value ETF | VONV | 9 | 1.17% |
| Vanguard Health Care ETF | VHT | 3 | 6.45% |
| WisdomTree U.S. Quality Dividend Growth Fund | DGRW | 9 | 2.36% |
Funds with AbbVie among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free